Last updated 2026-07-26
- Raised Follow-on PO, Apr 2014
Total raised
—
Stage
Public
Founded
2011
Headcount
20
HQ
Bnei Brak, Israel
Sector
Health Tech & Life Sciences
About
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented Veto Cell technology enables safe and selective tuning of immune responses. Veto Cells are white blood cells taken from either the patient or a healthy third-party donor, processed to activate their inherent “attacker blocking” capability. The company is developing therapies for stem cell transplantation, cancer treatment, organ transplants, and non-malignant diseases like sickle cell anemia and type 1 diabetes. Cell Source licenses its technology from the Weizmann Institute of Science in Israel.
Funding history · 1 round · — total
2014-04
Follow-on PO
Undisclosed
Headcount over time
From 3 (2019-01) to 20 (2025-04) · +17 (+567%) · 4 points · source: Finder history + radar grounding
Q&A
- What is Cell Source's primary focus?
- Cell Source is a biotechnology company developing cell therapy treatments based on the management of immune tolerance, utilizing its patented Veto Cell technology.
- When did Cell Source last raise funding?
- In April 2024, Cell Source raised $4,760,170 in Convertible Debt.
- What is the status of Cell Source's Veto Cell clinical trial?
- In November 2024, Cell Source shared promising interim results from its Veto Cell clinical trial.
- Where is Cell Source headquartered?
- Cell Source is headquartered in Bnei Brak, Israel, with an additional office in New York, USA.
- What was Cell Source's total funding raised to date?
- Cell Source has raised a total of $21,540,000 in funding.
- What was Cell Source's most recent presentation at a conference?
- In May 2026, Cell Source presented breakthrough developments for mismatched donor stem cell and organ transplants and off-the-shelf CAR-T cell therapy at the LD Micro Invitational Conference in Los Angeles.
- How many employees does Cell Source currently have?
- Cell Source has 11-50 employees.
- When did Cell Source become a public company?
- Cell Source became public on OTC in May 2014.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cell-source.com |
|---|
Identifiers & details
| Legal name | CELL SOURCE, INC. |
|---|---|
| Founded | 2011-9 |
| Employees (exact) | 20 |
| Offices | New York |
| Market cap | $22.5M |
| Status reason | Public on OTC on May, 2014; |
Radar intelligence
Patents
| EPO | 27 |
|---|
Web history (Wayback)
| Domain | cell-source.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514669761 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-09-15 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הטחנה 1 כפר סבא |